Sulfoxide-containing aromatic nitrogen mustards as hypoxia-directed bioreductive cytotoxins
ZY Sun, E Botros, AD Su, Y Kim, E Wang… - Journal of medicinal …, 2000 - ACS Publications
A series of diaryl and alkylaryl sulfoxide-containing nitrogen mustards were synthesized
and evaluated for their hypoxia-selective cytotoxicity against V-79 cells in vitro as well as for …
and evaluated for their hypoxia-selective cytotoxicity against V-79 cells in vitro as well as for …
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor
A Ghosal, Y Yuan, W Tong, AD Su, C Gu… - Drug metabolism and …, 2011 - ASPET
Boceprevir (SCH 503034), a protease inhibitor, is under clinical development for the treatment
of human hepatitis C virus infections. In human liver microsomes, formation of oxidative …
of human hepatitis C virus infections. In human liver microsomes, formation of oxidative …
Identification of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar)
…, W Tong, N Hapangama, Y Yuan, AD Su… - Drug metabolism and …, 2006 - ASPET
Lonafarnib (Sarasar), a farnesyl transferase inhibitor, is currently under development for the
treatment of solid tumors. Incubation of lonafarnib with human liver microsomes resulted in …
treatment of solid tumors. Incubation of lonafarnib with human liver microsomes resulted in …
Identification of human UDP‐glucuronosyltransferase enzyme (s) responsible for the glucuronidation of 3‐hydroxydesloratadine
…, Y Yuan, N Hapangama, AD Su… - … & drug disposition, 2004 - Wiley Online Library
Desloratadine is a non‐sedating antihistamine recently approved for the treatment of seasonal
allergic rhinitis. The major metabolite of desloratadine in human plasma and urine is the …
allergic rhinitis. The major metabolite of desloratadine in human plasma and urine is the …
Identification of unstable metabolites of Lonafarnib using liquid chromatography‐quadrupole time‐of‐flight mass spectrometry, stable isotope incorporation and ion …
W Tong, SK Chowdhury, AD Su, W Feng… - Journal of mass …, 2006 - Wiley Online Library
Structural characterization of unstable metabolites and other drug‐derived entities poses a
serious challenge to the analytical chemist using instrumentation such as LC‐MS and LC‐MS/…
serious challenge to the analytical chemist using instrumentation such as LC‐MS and LC‐MS/…
Quantitation of Parent Drug and Its Unstable Metabolites by in Situ Coulometric Oxidation and Liquid Chromatography− Tandem Mass Spectrometry
W Tong, SK Chowdhury, AD Su, KB Alton - Analytical chemistry, 2010 - ACS Publications
Recent FDA and ICH guidances on safety testing of drug metabolites have challenged the
way we traditionally think about quantitative bioanalytical methods. Such assays, in general, …
way we traditionally think about quantitative bioanalytical methods. Such assays, in general, …
Metabolism of loratadine and further characterization of its in vitro metabolites
…, R Ramanathan, Y Yuan, X Lu, ADI Su… - Drug metabolism …, 2009 - ingentaconnect.com
The present study demonstrated that in addition to CYP3A4 and CYP2D6, the metabolism
of loratadine is also catalyzed by CYP1A1, CYP2C19, and to a lesser extent by CYP1A2, …
of loratadine is also catalyzed by CYP1A1, CYP2C19, and to a lesser extent by CYP1A2, …
Metabolism and disposition of a novel B-cell lymphoma-2 inhibitor venetoclax in humans and characterization of its unusual metabolites
H Liu, MJ Michmerhuizen, Y Lao, K Wan… - Drug Metabolism and …, 2017 - ASPET
Venetoclax (ABT-199), a B-cell lymphoma-2 (Bcl-2) protein inhibitor, is currently in clinical
development for the treatment of hematologic malignancies. We characterized the absorption, …
development for the treatment of hematologic malignancies. We characterized the absorption, …
[PDF][PDF] Absorption, metabolism, and excretion of a Novel Bcl-2 Inhibitor venetoclax in humans
H Liu, MJ Michmerhuizen, Y Lao, K Wan… - Drug Metabolism and …, 2016 - researchgate.net
Venetoclax (ABT-199) is a Bcl-2 protein inhibitor and is currently in clinical development for
the treatment of hematological malignancies. The objective of this study was to characterize …
the treatment of hematological malignancies. The objective of this study was to characterize …
[PDF][PDF] CHARACTERIZATION OF HUMAN LIVER ENZYMES INVOLVED IN THE BIOTRANSFORMATION OF BOCEPREVIR, A HCV PROTEASE INHIBITOR
K Chowdhury, NS Kishnani, KB Alton - 2010 - Citeseer
Boceprevir (SCH 503034), a protease inhibitor, is under clinical development for the treatment
of human hepatitis C virus (HCV) infections. In human liver microsomes, formation of …
of human hepatitis C virus (HCV) infections. In human liver microsomes, formation of …